Organization
Air Force Medical University
2 abstracts
Abstract
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer.Org: Department of Thyroid, Breast, and Vascular Surgery at Xijing Hospital, Air Force Medical University,
Abstract
Clinical and biological heterogeneity in triple-negative breast cancer and HER2-low.Org: Tangdu Hospital, Air Force Medical University, Xi'an, China,